---
title: 'TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas:
  Implications for Targeted Therapy'
date: '2023-12-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38148663/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231228170629&v=2.18.0
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Immune checkpoint inhibitors against Programmed Cell Death Protein 1/Programmed
  Cell (PD-1/PD-L1) and CTLA-4/B7 axes have had limited success in hematologic malignancies,
  requiring the need to explore alternative targets such as T-cell immunoreceptor
  with Ig and ITIM domains (TIGIT)/CD155 to improve durable clinical responses. We
  undertook this study to investigate the expression profile of TIGIT such that the
  potential efficacy of TIGIT blockade could be mapped among lymphoma subtypes. ...
disable_comments: true
---
Immune checkpoint inhibitors against Programmed Cell Death Protein 1/Programmed Cell (PD-1/PD-L1) and CTLA-4/B7 axes have had limited success in hematologic malignancies, requiring the need to explore alternative targets such as T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/CD155 to improve durable clinical responses. We undertook this study to investigate the expression profile of TIGIT such that the potential efficacy of TIGIT blockade could be mapped among lymphoma subtypes. ...